Allergan gets FDA okay for paediatric Botox useThe FDA has approved Allergan’s Botox to treat lower-limb spasticity in children, further extending the use of the Share XAllergan gets FDA okay for paediatric Botox usehttps://pharmaphorum.com/news/allergan-gets-fda-okay-for-paediatric-botox-use/
Ipsen adds Blueprint’s FOP rare disease drug to pipeline for $535mIpsen has added to its rare diseases pipeline after striking an agreement with US biotech Blueprint for a Share XIpsen adds Blueprint’s FOP rare disease drug to pipeline for $535mhttps://pharmaphorum.com/news/ipsen-adds-blueprints-fop-rare-disease-drug-to-pipeline-for-535m/
Ipsen on neurotoxin research: the pharmaphorum podcastFor episode 7 of the pharmaphorum podcast I spoke to Ipsen’s Philippe Picaut about neurotoxin research, with a Share XIpsen on neurotoxin research: the pharmaphorum podcasthttps://pharmaphorum.com/podcast/ipsen-neurotoxin-research/
Ipsen launches new syringe for rare disease blockbusterIpsen will be launching a new pre-filled syringe for its blockbuster rare disease drug Somatuline (lanreotide) in the Share XIpsen launches new syringe for rare disease blockbusterhttps://pharmaphorum.com/news/ipsen-launches-new-syringe-for-rare-disease-blockbuster/
Ipsen to buy rare disease firm Clementia for up to $1.31bnFrance’s Ipsen has agreed to buy Canadian rare diseases biotech Clementia Pharmaceuticals in a deal worth up to Share XIpsen to buy rare disease firm Clementia for up to $1.31bnhttps://pharmaphorum.com/news/ipsen-to-buy-rare-disease-firm-clementia-for-up-to-1-31bn/
Chinese patients to get new drugs before UK after Brexit – says CEOUS, European, Japanese and Chinese patients could get novel medicines ahead of patients in the UK after Brexit, Share XChinese patients to get new drugs before UK after Brexit – says CEOhttps://pharmaphorum.com/news/chinese-patients-new-drugs-before-uk-brexit-ceo/
Ipsen warns over medicine supplies amid Brexit uncertaintyFrance’s Ipsen has become the latest pharma company to warn about the impact of Brexit on the pharma Share XIpsen warns over medicine supplies amid Brexit uncertaintyhttps://pharmaphorum.com/news/ipsen-warns-over-medicine-supplies-amid-brexit-uncertainty/
EU approves Ipsen’s Cabometyx in second line liver cancerThe European Commission has approved Ipsen’s Cabometyx for liver cancer, in adults previously treated with Bayer’s Nexavar. The Share XEU approves Ipsen’s Cabometyx in second line liver cancerhttps://pharmaphorum.com/news/european-commission-cabometyx/
EU regulators back Ipsen cancer drug in new liver cancer useIpsen’s bid to build a cancer franchise around its Cabometyx (cabozantinib) is gathering pace after European regulators backed Share XEU regulators back Ipsen cancer drug in new liver cancer usehttps://pharmaphorum.com/news/eu-regulators-cabometyx-liver/
